trial · primary record
Giredestrant
Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 373 |
| Primary completion | 2027-06-15 |
| Primary endpoint | Progression-Free Survival, as Determined by the Investigator According to RECIST v1.1, in the ESR1m Subpopulation and ITT Population |
| Registry ID | NCT05306340 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:44.266Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05306340
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Giredestrant · compound